|
Gene: SPRTN |
Gene summary for SPRTN |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPRTN | Gene ID | 83932 |
Gene name | SprT-like N-terminal domain | |
Gene Alias | C1orf124 | |
Cytomap | 1q42.2 | |
Gene Type | protein-coding | GO ID | GO:0000731 | UniProtAcc | Q9H040 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83932 | SPRTN | LZE2T | Human | Esophagus | ESCC | 4.41e-02 | 4.04e-01 | 0.082 |
83932 | SPRTN | LZE4T | Human | Esophagus | ESCC | 8.42e-04 | 1.41e-01 | 0.0811 |
83932 | SPRTN | LZE7T | Human | Esophagus | ESCC | 1.20e-08 | 4.00e-01 | 0.0667 |
83932 | SPRTN | LZE24T | Human | Esophagus | ESCC | 7.29e-10 | 2.62e-01 | 0.0596 |
83932 | SPRTN | LZE21T | Human | Esophagus | ESCC | 3.90e-02 | 1.45e-01 | 0.0655 |
83932 | SPRTN | P1T-E | Human | Esophagus | ESCC | 3.65e-04 | 3.20e-01 | 0.0875 |
83932 | SPRTN | P2T-E | Human | Esophagus | ESCC | 5.88e-23 | 3.87e-01 | 0.1177 |
83932 | SPRTN | P4T-E | Human | Esophagus | ESCC | 1.79e-12 | 2.66e-01 | 0.1323 |
83932 | SPRTN | P5T-E | Human | Esophagus | ESCC | 3.47e-13 | 2.95e-01 | 0.1327 |
83932 | SPRTN | P8T-E | Human | Esophagus | ESCC | 1.99e-10 | 1.28e-01 | 0.0889 |
83932 | SPRTN | P9T-E | Human | Esophagus | ESCC | 1.61e-12 | 2.59e-01 | 0.1131 |
83932 | SPRTN | P10T-E | Human | Esophagus | ESCC | 5.85e-26 | 4.89e-01 | 0.116 |
83932 | SPRTN | P11T-E | Human | Esophagus | ESCC | 2.63e-09 | 3.66e-01 | 0.1426 |
83932 | SPRTN | P12T-E | Human | Esophagus | ESCC | 6.47e-20 | 3.49e-01 | 0.1122 |
83932 | SPRTN | P15T-E | Human | Esophagus | ESCC | 3.17e-13 | 3.24e-01 | 0.1149 |
83932 | SPRTN | P16T-E | Human | Esophagus | ESCC | 1.19e-18 | 3.15e-01 | 0.1153 |
83932 | SPRTN | P17T-E | Human | Esophagus | ESCC | 1.32e-02 | 1.13e-01 | 0.1278 |
83932 | SPRTN | P19T-E | Human | Esophagus | ESCC | 1.30e-02 | 2.84e-01 | 0.1662 |
83932 | SPRTN | P20T-E | Human | Esophagus | ESCC | 9.99e-15 | 3.18e-01 | 0.1124 |
83932 | SPRTN | P21T-E | Human | Esophagus | ESCC | 1.88e-16 | 3.78e-01 | 0.1617 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:1903320111 | Esophagus | ESCC | regulation of protein modification by small protein conjugation or removal | 181/8552 | 242/18723 | 1.80e-20 | 2.60e-18 | 181 |
GO:0031396111 | Esophagus | ESCC | regulation of protein ubiquitination | 154/8552 | 210/18723 | 2.70e-16 | 2.04e-14 | 154 |
GO:000941113 | Esophagus | ESCC | response to UV | 115/8552 | 149/18723 | 3.29e-15 | 1.93e-13 | 115 |
GO:007189716 | Esophagus | ESCC | DNA biosynthetic process | 127/8552 | 180/18723 | 1.04e-11 | 3.85e-10 | 127 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:190332216 | Esophagus | ESCC | positive regulation of protein modification by small protein conjugation or removal | 99/8552 | 138/18723 | 4.39e-10 | 1.16e-08 | 99 |
GO:003139816 | Esophagus | ESCC | positive regulation of protein ubiquitination | 82/8552 | 119/18723 | 2.41e-07 | 3.64e-06 | 82 |
GO:00063012 | Esophagus | ESCC | postreplication repair | 26/8552 | 31/18723 | 1.32e-05 | 1.21e-04 | 26 |
GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
GO:000941611 | Esophagus | ESCC | response to light stimulus | 183/8552 | 320/18723 | 2.03e-05 | 1.76e-04 | 183 |
GO:0019985 | Esophagus | ESCC | translesion synthesis | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
GO:190332020 | Oral cavity | OSCC | regulation of protein modification by small protein conjugation or removal | 165/7305 | 242/18723 | 2.52e-20 | 3.99e-18 | 165 |
GO:003139620 | Oral cavity | OSCC | regulation of protein ubiquitination | 143/7305 | 210/18723 | 1.01e-17 | 9.80e-16 | 143 |
GO:00094114 | Oral cavity | OSCC | response to UV | 99/7305 | 149/18723 | 1.01e-11 | 3.70e-10 | 99 |
GO:005160410 | Oral cavity | OSCC | protein maturation | 170/7305 | 294/18723 | 3.97e-11 | 1.28e-09 | 170 |
GO:000931416 | Oral cavity | OSCC | response to radiation | 241/7305 | 456/18723 | 9.76e-10 | 2.40e-08 | 241 |
GO:19033227 | Oral cavity | OSCC | positive regulation of protein modification by small protein conjugation or removal | 88/7305 | 138/18723 | 3.24e-09 | 7.39e-08 | 88 |
GO:00718979 | Oral cavity | OSCC | DNA biosynthetic process | 106/7305 | 180/18723 | 4.86e-08 | 8.95e-07 | 106 |
GO:00313986 | Oral cavity | OSCC | positive regulation of protein ubiquitination | 75/7305 | 119/18723 | 9.46e-08 | 1.65e-06 | 75 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPRTN | SNV | Missense_Mutation | novel | c.1405N>C | p.Asn469His | p.N469H | Q9H040 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
SPRTN | SNV | Missense_Mutation | novel | c.651N>G | p.Asn217Lys | p.N217K | Q9H040 | protein_coding | tolerated(0.13) | benign(0.119) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SPRTN | SNV | Missense_Mutation | novel | c.1013N>T | p.Ala338Val | p.A338V | Q9H040 | protein_coding | deleterious(0.04) | benign(0.144) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SPRTN | SNV | Missense_Mutation | novel | c.908N>C | p.Lys303Thr | p.K303T | Q9H040 | protein_coding | tolerated(0.08) | benign(0.021) | TCGA-EY-A1GD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPRTN | SNV | Missense_Mutation | novel | c.739N>A | p.Ala247Thr | p.A247T | Q9H040 | protein_coding | tolerated(1) | benign(0) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPRTN | SNV | Missense_Mutation | novel | c.1056A>G | p.Ile352Met | p.I352M | Q9H040 | protein_coding | tolerated(0.06) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
SPRTN | SNV | Missense_Mutation | rs140605242 | c.469N>A | p.Asp157Asn | p.D157N | Q9H040 | protein_coding | deleterious(0.04) | benign(0.26) | TCGA-SL-A6JA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPRTN | insertion | Frame_Shift_Ins | novel | c.1328_1329insAGCCTTTTGG | p.Asn443LysfsTer16 | p.N443Kfs*16 | Q9H040 | protein_coding | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SPRTN | insertion | Frame_Shift_Ins | rs567805129 | c.1256_1257insT | p.Ile422TyrfsTer11 | p.I422Yfs*11 | Q9H040 | protein_coding | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SPRTN | deletion | Frame_Shift_Del | c.1257delN | p.Phe421LeufsTer7 | p.F421Lfs*7 | Q9H040 | protein_coding | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |